Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors
- PMID: 24355521
- PMCID: PMC3962950
- DOI: 10.1016/j.bbmt.2013.12.001
Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors
Abstract
The number of survivors after allogeneic hematopoietic stem cell transplantation (HSCT) continues to increase, yet their survivorship experience has not been fully characterized. This study examines the health status and health-related quality of life (HRQL) of HSCT survivors. The aims of the study were to: (1) explore the baseline and change over time in these health outcomes, and (2) characterize subgroups experiencing adverse outcomes. In this longitudinal study, adults who survived >3 years from date of allogeneic HSCT completed a series of patient-reported outcome measures annually, including measures of health status, HRQL, and symptoms. Data were analyzed using hierarchical linear modeling. Subjects (N = 171) were on average 44 (±13.5) years of age and primarily male (62.6%); 40% were Hispanic. Mean scores for physical and mental health and HRQL were preserved relative to population norms. Hierarchical linear modeling revealed no significant change in the mean trajectories of these outcomes, although significant between-individual variability was observed. When controlling for demographic and clinical factors, physical symptom distress negatively affected all outcomes. The impact of symptom distress on physical health varied based on time since HSCT; impairment in physical health was greatest in survivors experiencing high symptom distress and who were within the first decade post transplantation. Extended treatment with systemic immunosuppressive therapy also predicted inferior physical health. These findings suggest that patient-centered outcomes are preserved relative to normative values and are generally stable after allogeneic HSCT, although survivors with persistent symptoms and those receiving systemic immunosuppression experience impairments in health status and HRQL.
Keywords: Allogeneic hematopoietic stem cell transplantation; Fatigue; Functional status; Health-related quality of life; Symptom experience.
Published by Elsevier Inc.
Conflict of interest statement
Authors’ Disclosures of Potential Conflicts of Interest
The authors indicated no potential conflicts of interest.
Figures
Similar articles
-
Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.Biol Blood Marrow Transplant. 2010 Aug;16(8):1162-70. doi: 10.1016/j.bbmt.2010.03.005. Epub 2010 Mar 17. Biol Blood Marrow Transplant. 2010. PMID: 20302959 Free PMC article.
-
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol.Health Qual Life Outcomes. 2011 Apr 17;9:24. doi: 10.1186/1477-7525-9-24. Health Qual Life Outcomes. 2011. PMID: 21496339 Free PMC article.
-
The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT).Support Care Cancer. 2008 Nov;16(11):1243-54. doi: 10.1007/s00520-008-0420-6. Epub 2008 Mar 6. Support Care Cancer. 2008. PMID: 18322708 Free PMC article.
-
Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation.Semin Hematol. 2012 Jan;49(1):104-9. doi: 10.1053/j.seminhematol.2011.10.004. Semin Hematol. 2012. PMID: 22221790 Review.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Everyday life following hematopoietic stem cell transplantation: decline in physical symptoms within the first month and change-related predictors.Qual Life Res. 2018 Jan;27(1):125-135. doi: 10.1007/s11136-017-1705-3. Epub 2017 Sep 12. Qual Life Res. 2018. PMID: 28900828 Free PMC article.
-
Fatigue predicts impaired social adjustment in survivors of allogeneic hematopoietic cell transplantation (HCT).Support Care Cancer. 2019 Apr;27(4):1355-1363. doi: 10.1007/s00520-018-4411-y. Epub 2018 Aug 22. Support Care Cancer. 2019. PMID: 30136024 Free PMC article.
-
What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?Ann Hematol. 2021 Jun;100(6):1377-1389. doi: 10.1007/s00277-021-04538-4. Epub 2021 May 6. Ann Hematol. 2021. PMID: 33954817 Free PMC article. Review.
-
Developing a supportive and palliative care intervention for patients with allogeneic stem cell transplantation: protocol of a multicentre mixed-methods study (allo-PaS).BMJ Open. 2023 Aug 31;13(8):e066948. doi: 10.1136/bmjopen-2022-066948. BMJ Open. 2023. PMID: 37652589 Free PMC article.
-
The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.Blood. 2015 May 21;125(21):3230-5. doi: 10.1182/blood-2014-10-567784. Epub 2015 Apr 7. Blood. 2015. PMID: 25852053 Free PMC article. Review.
References
-
- Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med. 2003;54:491–512. - PubMed
-
- Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant. 2001;27:899–916. - PubMed
-
- National Marrow Donor Program. Unrelated Search & Transplant - Trends in Allogeneic Transplants. National Marrow Donor Program. 2013
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical